SavedAdd your journal

Journals / Türk Onkoloji Dergisi / 2020 / Cilt: 35 - Sayı: 1

Evaluation of Hematological/Pathological Prognostic Factors and Oncological Outcomes of Patients with Locally Advanced Rectal Cancer Treated with Neoadjuvant Radiotherapy

Gülhan GÜLER AVCI
Pages
31–39
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

OBJECTIVEIn this study, we aimed to present our results of overall survival (OS), progression-free survival (PFS)and local control (LC) in approximately five years of follow-up of the patients with locally advancedrectal cancer who underwent neoadjuvant radiotherapy (RT) and to investigate both the pathologicaland hematological parameters that affect the survival.METHODSA total of 76 patients with a pathologic diagnosis of rectum adenocarcinoma and clinical stage I- IVAwho underwent neoadjuvant RT between August 2014 and March 2019 were evaluated retrospectivelyin this study.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:OBJECTIVEIn this study, we aimed to present our results of overall survival (OS), progression-free survival (PFS)and local control (LC) in approximately five years of follow-up of the patients with locally advancedrectal cancer who underwent neoadjuvant radiotherapy (RT) and to investigate both the pathologicaland hematological parameters that affect the survival.METHODSA total of 76 patients with a pathologic diagnosis of rectum adenocarcinoma and clinical stage I- IVAwho underwent neoadjuvant RT between August 2014 and March 2019 were evaluated retrospectivelyin this study.
📊
Key Findings & Data:Eighty-five percent of the patients received 45/50 Gy doses of RT concomitantly with oralcapecitabine.
💡
Conclusion & Impact:CEA’s response to neoadjuvant treatment (NAT) significantly increased OS and PFS.CONCLUSIONAdverse tumor histology, the prolonged time from completion of RT to surgery, CEA’s response to NATand pre RT Hb levels were essential factors that affect survival.
🔬Design:Research Article
📍Scope:2014 Verileri
⚙️Variables:Domain Parameters

Abstract

OBJECTIVEIn this study, we aimed to present our results of overall survival (OS), progression-free survival (PFS)and local control (LC) in approximately five years of follow-up of the patients with locally advancedrectal cancer who underwent neoadjuvant radiotherapy (RT) and to investigate both the pathologicaland hematological parameters that affect the survival.METHODSA total of 76 patients with a pathologic diagnosis of rectum adenocarcinoma and clinical stage I- IVAwho underwent neoadjuvant RT between August 2014 and March 2019 were evaluated retrospectivelyin this study. Eighty-five percent of the patients received 45/50 Gy doses of RT concomitantly with oralcapecitabine. Fifty-eight patients (78.4%) underwent surgery. The median time between the completionof RT and surgery was 65 days.RESULTSThe median follow-up was 25 months. The 2-year OS, PFS and LC rates were 85%, 83.7% and 85.2%, respectively. Positive radial surgical margin was a significant prognostic factor for OS and PFS, but not forLC. The factor affecting OS, PFS and LC was adverse tumor histology (undifferentiated). The prolongationof the time from completion of RT to surgery caused OS and LC to deteriorate. Local control significantlydecreased in patients without concomitant chemotherapy. Among all the hematological parameters (e.g.albumin, WBC, platelet, neutrophil, CA 19-9), only pre RT Hb levels significantly correlated with OS butnot with PFS. CEA’s response to neoadjuvant treatment (NAT) significantly increased OS and PFS.CONCLUSIONAdverse tumor histology, the prolonged time from completion of RT to surgery, CEA’s response to NATand pre RT Hb levels were essential factors that affect survival.

🔖

Cite This Article

AVCI, G. G. (2022). Evaluation of Hematological/Pathological Prognostic Factors and Oncological Outcomes of Patients with Locally Advanced Rectal Cancer Treated with Neoadjuvant Radiotherapy. Türk Onkoloji Dergisi, Cilt: 35 - Sayı: 1, 31–39. https://ajindex.com/articles/639137

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58(2):71−96
  2. NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA 1990;264(11):1444−50
  3. Wibe A, Møller B, Norstein J, Carlsen E, Wiig JN, Heald RJ, et al. A national strategic change in treatment policy for rectal cancer--implementation of total mesorectal excision as routine treatment in Norway. A national audit. Dis Colon Rectum 2002;45(7):857−66
  4. Kapiteijn E, Putter H, van de Velde CJ; Cooperative investigators of the Dutch ColoRectal Cancer Group. Impact of the introduction and training of total mesorectal excision on recurrence and survival in rectal cancer in The Netherlands. Br J Surg 2002;89(9):1142−9
  5. Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R et al; German Rectal Cancer Study Group. Preoperative versus postoperative 6 chemoradiotherapy for rectal cancer. N Engl J Med 2004;351(17):1731−40
  6. Gérard JP, Conroy T, Bonnetain F, Bouché O, Chapet O, Closon-Dejardin MT, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol 2006;24(28):4620−5
  7. Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, et al; EORTC Radiotherapy Group Trial 22921. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006;355(11):1114−23
  8. Glynne-Jones R, Wyrwicz L, Tiret E, Brown G, Rödel C, Cervantes A, et al. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017;28(suppl_4):iv22-iv40
  9. Benson AB, Venook AP, Al-Hawary MM, Cederquist L, Chen YJ, Ciombor KK, et al. Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2018;16(7):874−901. 10. van Gijn W, Marijnen CA, Nagtegaal ID, Kranenbarg EM, Putter H, Wiggers T, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol 2011;12(6):575−82. 11.Valentini V, van Stiphout RG, Lammering G, Gambacorta MA, Barba MC, Bebenek M, et al. Nomograms for predicting local recurrence, distant metastases, and overall survival for patients with locally advanced rectal cancer on the basis of European randomized clinical trials. J Clin Oncol 2011;29(23):3163−72. 12.Park IJ, You YN, Agarwal A, Skibber JM, Rodri